Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Abstract The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of checkpoint molecules: anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason Hu, Peng Luo, Jian Zhang, Zaoqu Liu, Yun Peng, Zhixiong Liu, Lanhua Tang, Quan Cheng
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2022-08-01
Σειρά:	Journal of Hematology & Oncology
Θέματα:	Immunotherapy Immune checkpoint Clinical trial Targeted drugs
Διαθέσιμο Online:	https://doi.org/10.1186/s13045-022-01325-0
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!